Research Progress on Targeted Therapy and Resistance Mechanisms of Malignant Melanoma

Yifan LIU; Xing LUO; Tianci SONG; Zhihui YANG

doi:10.12259/j.issn.2095-610X.S20250222

Volume 46 Issue 2

Feb. 2025

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2025 > 46(2): 158-163

Yifan LIU, Xing LUO, Tianci SONG, Zhihui YANG. Research Progress on Targeted Therapy and Resistance Mechanisms of Malignant Melanoma[J]. Journal of Kunming Medical University, 2025, 46(2): 158-163. doi: 10.12259/j.issn.2095-610X.S20250222

Citation:

Yifan LIU, Xing LUO, Tianci SONG, Zhihui YANG. Research Progress on Targeted Therapy and Resistance Mechanisms of Malignant Melanoma[J]. Journal of Kunming Medical University, 2025, 46(2): 158-163. doi: 10.12259/j.issn.2095-610X.S20250222

Citation:

PDF( 545 KB)

Research Progress on Targeted Therapy and Resistance Mechanisms of Malignant Melanoma

doi: 10.12259/j.issn.2095-610X.S20250222

Yifan LIU^{1, 2},
Xing LUO^{2, 3},
Tianci SONG⁴,
Zhihui YANG^{2, 3
,
,}

1.
School of Basic Medical Sciences，Southwest Medical University，Luzhou Sichuan 646000
2.
Key Laboratory for Precision Pathological Diagnosis of Major Diseases，Luzhou Sichuan 646000
3.
Affiliated Hospital of Southwest Medical University，Luzhou Sichuan 646000
4.
School of Clinical Medicine，Qilu Medical University，Zibo Shandong 255300，China

Received Date: 2024-07-19
Available Online: 2025-01-05
Publish Date: 2025-02-18

Abstract

Abstract

Malignant melanoma is an extremely aggressive tumor that can be surgically treated in its early stage. In advanced stages, the invasive and proliferative capabilities of melanoma cells continue to increase, and traditional treatment methods such as radiotherapy, chemotherapy, and immunotherapy have limited efficacy, resulting in poor patient prognosis. Due to the presence of mutations in multiple molecular pathways in malignant melanoma, targeted therapy is now regarded as a more viable treatment option for patients with advanced malignant melanoma, with most patients benefiting from it. However, the development of drug resistance to targeted therapy has always been a serious challenge, as the emergence of resistance limits the efficacy. Therefore, it is necessary to explore the mechanism and drug resistance of targeted therapy of malignant melanoma.
- Malignant melanoma,
- Targeted therapy,
- Drug resistance mechanisms

FullText(HTML)

References(47)

References

[1]	Long G V,Swetter S M,Menzies A M,et al. Cutaneous melanoma[J]. Lancet,2023,402(10400):485-502. doi: 10.1016/S0140-6736(23)00821-8
[2]	Patel H,Yacoub N,Mishra R,et al. Current advances in the treatment of BRAF-mutant melanoma[J]. Cancers (Basel),2020,12(2):482. doi: 10.3390/cancers12020482
[3]	Aya F,Lanuza-Gracia P,Gonz á lez-P é rez A,et al. Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma[J]. Cell Rep,2024,43(4):114048. doi: 10.1016/j.celrep.2024.114048
[4]	Gerosa L,Chidley C,Fröhlich F,et al. Receptor-driven ERK pulses reconfigure MAPK signaling and enable persistence of drug-adapted BRAF-mutant melanoma cells[J]. Cell Syst,2020,11(5):478-494. doi: 10.1016/j.cels.2020.10.002
[5]	Boutros A,Croce E,Ferrari M,et al. The treatment of advanced melanoma: current approaches and new challenges[J]. Crit Rev Oncol Hematol,2024,196:104276. doi: 10.1016/j.critrevonc.2024.104276
[6]	Klobuch S,Seijkens T T P,Schumacher T N,et al. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma[J]. Nat Rev Clin Oncol,2024,21(3):173-184. doi: 10.1038/s41571-023-00848-w
[7]	Fateeva A,Eddy K,Chen S. Current state of melanoma therapy and next steps: battling therapeutic resistance[J]. Cancers (Basel),2024,16(8):1571. doi: 10.3390/cancers16081571
[8]	Boz Er A B,Sheldrake H M,Sutherland M. Overcoming vemurafenib resistance in metastatic melanoma: Targeting integrins to improve treatment efficacy[J]. Int J Mol Sci,2024,25(14):7946. doi: 10.3390/ijms25147946
[9]	刘欣,张晓伟,罗志国. BRAF突变型黑色素瘤治疗进展[J]. 中国肿瘤临床,2022,49(10):487-491.
[10]	Menzies A M,Long G V. Dabrafenib and trametinib,alone and in combination for BRAF-mutant metastatic melanoma[J]. Clin Cancer Res,2014,20(8):2035-2043. doi: 10.1158/1078-0432.CCR-13-2054
[11]	Spagnolo F,Ghiorzo P,Orgiano L,et al. BRAF-mutant melanoma: Treatment approaches,resistance mechanisms,and diagnostic strategies[J]. Onco Targets Ther,2015,16;8:157-168.
[12]	Larkin J,Ascirto P A,Dréno B,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma[J]. N Engl J Med,2014,371(20):1867-1876. doi: 10.1056/NEJMoa1408868
[13]	Robert C,Karaszewska B,Schachter J,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib[J]. N Engl J Med,2015,372(1):30-39. doi: 10.1056/NEJMoa1412690
[14]	Long G V,Flaerty K T,Stroyakovskiy D,et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study[J]. Ann Oncol,2017,28(7):1631-1639. doi: 10.1093/annonc/mdx176
[15]	王欣欣,田红旗. MEK抑制剂联合用药在黑色素瘤治疗中的应用研究进展[J]. 山东医药,2019,59(20):96-99.
[16]	Dummer R,Ascierto P A,Gogas H J,et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre,open-label,randomised phase 3 trial [J],Lancet Oncol,2018,19(5): 603-615.
[17]	Schadendorf D,Dummer R,Flaherty KT,et al. COLUMBUS 7-year update: A randomized,open-label,phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma[J]. Eur J Cancer,2024,204:114073. doi: 10.1016/j.ejca.2024.114073
[18]	Morris E J,Jha S,Restaino C R,et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors[J]. Cancer Discov,2013,3(7):74250.
[19]	Bhagwat S V,McMillen W T,Cai S,et al. ERK inhibitor LY3214996 targets ERK pathway-driven cancers: A therapeutic approach toward precision medicine[J]. Mol Cancer Ther,2020,19(2):325-336. doi: 10.1158/1535-7163.MCT-19-0183
[20]	Shirley C A,Chhabra G,Amiri D,et al. Immune escape and metastasis mechanisms in melanoma: Breaking down the dichotomy[J]. Front Immunol,2024,15:1336023. doi: 10.3389/fimmu.2024.1336023
[21]	Zhu Z,Jin Y,Zhou J,et al. PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights,clinical efficacy,and future perspectives[J]. Mol Cancer,2024,23(1):146. doi: 10.1186/s12943-024-02059-y
[22]	Munir A Z,Gutierrez A,Qin J,et al. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4,PD1 and LAG3 in the heart[J]. Nat Rev Cancer,2024,24(8):540-553. doi: 10.1038/s41568-024-00715-5
[23]	Schadendorf D,Van Akkooi ACJ,Berking C,et al. Melanoma[J]. Lancet,2018,392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9
[24]	Wolchok J D,Chiarion-Sileni V,Gonzalez R,et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma[J]. J Clin Oncol,2022,40(2):127-137. doi: 10.1200/JCO.21.02229
[25]	Ribas A,Lawrence D,Atkinson V,et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma[J]. Nat Med,2019,25(6):936-940. doi: 10.1038/s41591-019-0476-5
[26]	陈述,梅玲蔚. 恶性黑色素瘤的靶向药物治疗进展[J]. 现代医药卫生,2022,38(7):1184-1188.
[27]	Zhou S,Abdihamid O,Tan F,et al. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST[J]. Cell Commun Signal,2024,22(1):153. doi: 10.1186/s12964-023-01411-x
[28]	Guo J,Carvajal R D,Dummer R,et al. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global,single-arm,phase II TEAM trial[J]. Ann Oncol,2017,28(6):1380-1387. doi: 10.1093/annonc/mdx079
[29]	谢永淳,邓思瑶,路顺. 黏膜黑色素瘤的免疫和靶向治疗研究进展[J]. 肿瘤预防与治疗,2022,35(8):751-758.
[30]	Shaw P,Dwivedi S K D,Bhattacharya R,et al. VEGF signaling: role in angiogenesis and beyond[J]. Biochim Biophys Acta Rev Cancer,2024,1879(2):189079. doi: 10.1016/j.bbcan.2024.189079
[31]	Perez D G,Suman V J,Fitch T R,et al. Phase 2 trial of carboplatin,weekly paclitaxel,and biweekly bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study,N047A[J]. Cancer,2009,115(1):119-127. doi: 10.1002/cncr.23987
[32]	Gouda M A,Thein K Z,Hong D S. Tissue-agnostic targeting of neurotrophic tyrosine receptor kinase fusions: Current approvals and future directions[J]. Cancers (Basel),2024,16(19):3395. doi: 10.3390/cancers16193395
[33]	Tangella L P,Clark M E,Gray E S. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review[J]. Biochim Biophys Acta Gen Subj,2021,1865(1):129736. doi: 10.1016/j.bbagen.2020.129736
[34]	Czarnecka A M,Bartnik E,Fiedorowicz M,et al. Targeted therapy in melanoma and Mechanisms of Resistance[J]. Int J Mol Sci,2020,21(13):4576. doi: 10.3390/ijms21134576
[35]	Maertens O,Johnson B,Hollstein P,et al. Elucidating distinct roles for NF1 in melanomagenesis[J]. Cancer Discov,2013,3(3):338-349. doi: 10.1158/2159-8290.CD-12-0313
[36]	Zhou P,Meng X,Nie Z,et al. PTEN: An emerging target in rheumatoid arthritis?[J]. Cell Commun Signal,2024,22(1):246.
[37]	Paraiso K H,Xiang Y,Rebecca V W,et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression[J]. Cancer Res,2011,71(7):2750-2760. doi: 10.1158/0008-5472.CAN-10-2954
[38]	Shi H,Hugo W,Kong X,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy[J]. Cancer Discov,2014,4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642
[39]	Johannessen C M,Boehm J S,Kim S Y,et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation[J]. Nature,2010,468(7326):968-972. doi: 10.1038/nature09627
[40]	Lehmann B D,Shaver T M,Johnson D B,et al. Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations[J]. Mol Cancer Res,2019,17(9):1842-1853. doi: 10.1158/1541-7786.MCR-19-0257
[41]	Kundu M,Butti R,Panda V K,et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer[J]. Mol Cancer,2024,23(1):92. doi: 10.1186/s12943-024-01990-4
[42]	Liu H,Tang L,Li Y,et al. Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes[J]. Mol Cancer,2024,23(1):20. doi: 10.1186/s12943-023-01928-2
[43]	Zhao K,Lu Y,Chen Y,et al. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells[J]. Exp Cell Res,2020,390(2):111942. doi: 10.1016/j.yexcr.2020.111942
[44]	Zhao K,Lu Y,Chen Y,et al. Dual inhibition of MAPK and JAK2/STAT3 pathways is critical for the treatment of BRAF mutant melanoma[J]. Mol Ther Oncolytics,2020,18:100-108. doi: 10.1016/j.omto.2020.06.004
[45]	Comunanza V,Corà D,Orso F,et al. VEGF blockade enhances the antitumor effect of BRAFV600E inhibition[J]. EMBO Mol Med,2017,9(2):219-237. doi: 10.15252/emmm.201505774
[46]	Leiphrakpam P D,Are C. PI3K/Akt/mTOR signaling pathway as a target for colorectal Cancer Treatment[J]. Int J Mol Sci,2024,25(6):3178. doi: 10.3390/ijms25063178
[47]	Shi H,Hugo W,Kong X,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy[J]. Cancer Discov,2014,4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642

Relative Articles(20)

Relative Articles

[1]	Zhixiao LI, Xia ZHENG, Chunling LI, Qingsheng LIU, Heng ZHANG. The Molecular Mechanism of miR-205-5p Targeting ERBB3 to Regulate PI3K/AKT/mTOR Pathway and Inhibit Angiogenesis in Hemorrhoids. Journal of Kunming Medical University, 2024, 45(6): 22-35. doi: 10.12259/j.issn.2095-610X.S20240604
[2]	Hui DING, Qing ZHOU, Ruzhou FENG, Ni ZHOU, Shinan ZHANG, Juan Liu. Comparison of the Therapeutic Effects of Two Methods for Removing Black Tooth Stain in Children. Journal of Kunming Medical University, 2023, 44(8): 133-138. doi: 10.12259/j.issn.2095-610X.S20230801
[3]	Cuihua FANG, Maohua PAN, Longcan ZHOU, Yucheng QIN, Yaming HUANG, Jia MA, Xi CHEN, Zhaoqing YANG. Current Status and Research Progress of Immunotherapy for Melanoma. Journal of Kunming Medical University, 2023, 44(5): 175-179. doi: 10.12259/j.issn.2095-610X.S20230519
[4]	Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, 2023, 44(7): 148-155. doi: 10.12259/j.issn.2095-610X.S20230708
[5]	Ting LI, Wei-Hua GUO. Research Progress of Glycolytic Reprogramming in Oral Squamous Cell Carcinoma. Journal of Kunming Medical University, 2023, 44(6): 155-161. doi: 10.12259/j.issn.2095-610X.S20230611
[6]	Chenxi LI, Zhuocen ZHA, Na LI, Lin LUO, Yang YANG, Wenlin CHEN. Selection of Intensive Adjuvant Therapy for Triple-positive Breast Cancer. Journal of Kunming Medical University, 2023, 44(10): 180-188. doi: 10.12259/j.issn.2095-610X.S20231020
[7]	Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927
[8]	Haixia ZHANG, Lei LI, Lei JIN, Peijing YE, Chuanzheng SUN. Clinical Features of 1,203 Melanoma Cases in Yunnan Cancer Hospital. Journal of Kunming Medical University, 2022, 43(8): 56-60. doi: 10.12259/j.issn.2095-610X.S20220808
[9]	Qiao LUO, Hong SHI, Shaobo WANG. Role of α7-nicotinic Acetylcholine Receptor in Occurrence，Development and Therapy of Lung Cancer. Journal of Kunming Medical University, 2022, 43(2): 145-149. doi: 10.12259/j.issn.2095-610X.S20220226
[10]	Xilan WU, Hong SHEN, Susheng SHI, Zhihui ZHANG, Lei GUO, Fang WANG. The Expression of PD-L1, BRAF^V600E, CD68 Protein and the Significance of Tumor Infiltrating Lymphocytes in the Diagnosis of Malignant Melanoma. Journal of Kunming Medical University, 2022, 43(9): 13-18. doi: 10.12259/j.issn.2095-610X.S20220923
[11]	Liu Hong Wei , Yao Jian Hui , Liu Peng Jun , Li Wei Min . . Journal of Kunming Medical University, 2020, 41(04): 18-24.
[12]	Zhu Zhong Shan , Yan Wen Hui , Li Xiao Bing , Yang Zhou , Bai Peng . Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis. Journal of Kunming Medical University, 2018, 39(08): 47-50.
[13]	Hu Yu Chong , Lu Jing Kun , Cui Meng Yao . . Journal of Kunming Medical University, 2017, 38(03): 27-30.
[14]	Qian Lu , Bian Li . Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms. Journal of Kunming Medical University, 2017, 38(08): 126-129.
[15]	Zhou JieYan . . Journal of Kunming Medical University,
[16]	Qing Chen . . Journal of Kunming Medical University, 2013, 34(01): 1-3.
[17]	Zhang Zhen Guang . . Journal of Kunming Medical University,
[18]	Xu Ke Dong . . Journal of Kunming Medical University,
[19]	Chen Xian Yu . . Journal of Kunming Medical University,
[20]	Chen Yong Sheng . . Journal of Kunming Medical University,